A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Authors :: Sheeba K. Thomas
Jatin J. Shah
Donna M. Weber
Ashley Morphey
Hans C. Lee
Robert Z. Orlowski
Michael L. Wang
Emily Wesson
Ralph J. Johnson
Lei Feng
Raymond Alexanian
Source :: American Journal of Hematology. 94
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Salvage therapy
Hematology
Drug resistance
medicine.disease
Clinical trial
Thalidomide
Internal medicine
medicine
Neoplasm
Progression-free survival
business
Dexamethasone
medicine.drug
Lenalidomide

Tools